Dexmedetomidine and Postoperative Gastrointestinal Recovery: A Critical Narrative Review of Direct Enteric and Opioid-Sparing Pathways.

Postoperative gastrointestinal dysfunction (POGD) remains an important barrier to recovery after abdominal and non-abdominal surgery. This critical narrative review evaluates whether dexmedetomidine improves postoperative gastrointestinal recovery through an independent direct prokinetic action or predominantly through opioid-sparing and other indirect recovery pathways. Positive trials and meta-analyses report earlier flatus, defecation, or oral intake in selected settings, but most also permit simultaneous reductions in opioid exposure, pain, postoperative nausea and vomiting (PONV), inflammatory biomarkers, or sympathetic stress. These co-occurring effects limit causal attribution. We therefore propose a context-dependent dual-pathway model in which an opioid-sparing indirect pathway and a biologically plausible non-opioid pathway contribute with weights that vary according to baseline opioid burden, enhanced recovery after surgery (ERAS) maturity, dose, timing, and inflammatory phenotype. The available evidence is most consistent with, but does not prove, an opioid-sparing-dominant explanation; independent enteric effects remain clinically unisolated. Counter-evidence from healthy volunteers, isolated intestine, and sepsis models also argues against a universal prokinetic property. Clinically, dexmedetomidine should be positioned as a context-dependent multimodal adjunct rather than a stand-alone prokinetic therapy. Opioid-standardized trials with validated gastrointestinal endpoints and prespecified mediation analyses are needed to distinguish the two pathways.